Arrowhead Pharmaceuticals Price Target Raised Following Positive Plozasiran Trial Results

Key Facts

In a move reflecting growing optimism within the biotech sector, Chardan Capital has raised its price target for Arrowhead Pharmaceuticals to $115. This positive revision follows the successful clinical performance of plozasiran, a drug developed for treating severe hypertriglyceridemia. According to reports, the drug met all primary and secondary endpoints in the SHASTA-3 and SHASTA-4 trials, significantly strengthening its path toward potential regulatory approval.

Phase 3 trial data revealed robust results, with patients receiving a 25 mg dose experiencing a median triglyceride reduction of 79%. The clinical findings highlight both the efficacy and a strong safety profile for the treatment. While the outlook remains bullish, analysts note that the stock has already surged 21% to reach a 52-week high, suggesting that much of the trial success may already be priced into current valuations.

On the macro front, broader market sentiment for growth stocks may be influenced by upcoming central bank communications, including a speech by Fed Governor Jefferson scheduled for late July 16, 2026, which could impact overall sector volatility.